Early research (Phase 1)Study completedNCT03028103
What this trial is testing
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal LymphomaMantle Cell Lymphoma+2 more
Epizyme, Inc. 32